Advertisement

Topics

Latest Diabetic Nephropathy - Kidney Disease NewsRSS

05:55 EDT 22nd September 2017 | BioPortfolio

Japan Ministry of Health, Labor and Welfare Approves Opdivo (nivolumab) for the Treatment of Patients with Unresectable Advanced or Recurrent Gastric Cancer Which Has Progressed After Chemotherapy

Opdivo is the first and only Immuno-Oncology treatment to demonstrate survival benefit in patients who underwent two or more prior treatments Opdivo is the first Immuno-Oncology agent anywhere in the world to receive approval for unresectable advanced or recurrent gastric cancer based on a Phase 3 study Bristol-Myers

Rob Lowe Hosts an Upcoming Episode of the "Success Files" Series on Alzheimer's Awareness

The educational program created for PBS Member Stations will discuss the prevalence of the disease. (PRWEB) September 22, 2017 "Success Files," a short- and long-form documentary style show featuring host Rob Lowe, explores the world of Alzheimer’s. Alzheimer’s is a disease estimated to affect the lives of more than 5 million Americans living with the disease. This according to info...

My Home Sleep Testing – Stance against Sleep Apnea

The recently introduced My Home Sleep Testing program allows patients to monitor their sleep apnea disease at an ease of staying at home. The program aims get patients rid of a fatal disease. Miami, FL (PRWEB) September 22, 2017 The dominant tech company INGIC has freshly contributed in the health sector of Florida by introducing My Home Sleep Testing program, a program that aims to help Sleep Ap...

Global Anthrax Partnering 2010 to 2017 [Report Updated: 01092017] Prices from USD $1495

The Global Anthrax Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and agr...

Global Coronary Artery Disease Partnering 2010 to 2017 [Report Updated: 01092017] Prices from USD $1495

The Global Coronary Artery Disease Partnering since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and agreemen...

Global Sexual Health Partnering 20102017: Deal trends, players and financials [Report Updated: 01092017] Prices from USD $2995

Global Sexual Health Partnering 2010 to 2017 provides the full collection of Sexual Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Trends in Sexual Health partnering dealsFinancial deal terms for headline, upfront and royalty by stage of developmentSexual Health partnering agreement structureSexual Health partnering contract documentsTop Sexu...

Global Human Papilloma Virus Partnering 2010 to 2017 [Report Updated: 01092017] Prices from USD $1495

The Global Human Papilloma Virus Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering...

D1 Agonist Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, D1 AgonistMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across D1 Agonist. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of D1 Agonist by development stage, therapy ...

Global Ebola Partnering 2010 to 2017 [Report Updated: 01092017] Prices from USD $1495

The Global Ebola Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and agree...

Global COPD Partnering 2010 to 2017 [Report Updated: 01092017] Prices from USD $1495

The Global COPD Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering deals and agreem...

Global Gastrointestinal Symptoms Partnering 2010 to 2017 [Report Updated: 01092017] Prices from USD $1495

The Global Gastrointestinal Symptoms Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partne...

BD intros 6-mm pen needle for injection pens

David Salazarhe BD Ultra-Fine micro pen needle 6 mm x 32 gauge is set for distribution in September, bringing a new needle length option to patients with diabetes who inject insulin. read more

Innoviva to Participate in Cantor Fitzgerald’s Global Healthcare Conference on September 26

Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d’Esparbes, SVP and Chief Financial Officer will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26 at 4:35 EDT, at the InterContinental New York Barclay Hotel in New York City. T...

Global Multiple Sclerosis Partnering 2010 to 2017 [Report Updated: 01092017] Prices from USD $1495

The Global Multiple Sclerosis Partnering Terms and Agreements since 2010 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. Trends in partnering deals Top deals by value Deals listed by company AZ, industry sector, stage of development, technology typeThe report provides understanding and access to the partnering de...

Cognitive decline associated with type 2 diabetes could be managed with early intervention

New research from the American Di

Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member

SAN FRANCISCO, Sept. 21, 2017 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that Jeff Ajer, Executive Vice President and Chief Commercial Officer of BioMarin, has been appointed as an independent director to Nektar's Board of Directors. Mr. Ajer has more than 25 years of biotechnology industry experience within rare disease and specialty medicine. "We are extremely pl...

Powering Precision Health 2017 To Kick Off With A Mission To Eradicate Disease

Top U.S. Medical Experts to Convene, Collaborate on New Precision Health Research; World-Renowned Dr. Ann McKee, Boston University, Dr. Raghu Kalluri, MD Anderson Cancer Center, and Nancy Frates of Ice Bucket Challenge to Headline Summit The nation’s first precision health summit designed to be the premiere forum for world-leading medical experts to ...

Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares

LEXINGTON, Mass., Sept. 21, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to endogenous aldehyde toxicity, today announced the closing of its previously announced underwritten public offering of 3,967,500 shares of its common stock, which...

Fatty Liver Disease Global Clinical Trials Review, H2, 2017

LONDON, Sept. 21, 2017 /PRNewswire/ -- Fatty Liver Disease Global Clinical Trials Review, H2, 2017SummaryGlobalData's clinical trial report, "Fatty Liver Disease Global Clinical Trials Review, H2, 2017" provides an overview of Fatty Liver Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Fatty Liver Disease. Report includes an overview of trial...

Poxel Reports Results for the First Half 2017 and Provides Corporate Update

Poxel will host an investor conference call today to discuss the First Half 2017 results at 1 pm ET (7 pm CET). To participate in the call, please use the dial-in numbers: US: +1 877-887-4163 FR: +33 (0)172001510 UK: +44 2030432440 Access Code: 11730055# POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company fo...

Global Pressure Ulcer Relief Products Industry

LONDON, Sept. 21, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Pressure Ulcer Relief Products in US$ Million.Download the full report: https://www.reportbuyer.com/product/5112920The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.Annual estimates and forecasts are provided for the period 2016 ...

Calcium pyrophosphate deposition disease linked to increased odds of RA, osteoporosis, hypomagnesemia

Calcium pyrophosphate deposition disease appears to be positively associated with increased odds of rheumatoid arthritis, hypomagnesemia and osteoporosis, according to findings.Researchers reviewed the Department of VA Corporate Data Warehouse to identify 25,157 patients with Calcium pyrophosphate deposition disease (CPDD) and who presented during a 4-year period. Patients with CPDD were sex- and ...

Leukotriene D4 Antagonist Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, Leukotriene D4 AntagonistMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Leukotriene D4 Antagonist. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of Leukotriene...

More than 85 medicines in development for Alzheimer’s disease

When Brian Kursonis started “blanking out” for moments at a time, a scan revealed plaques of a protein called amyloid in the brain, one sign of

Lisa Estrada, Fresenius Medical Care North America, Joins Movement to Raise $1 Million for Kidney Health

The National Kidney Foundation (NKF) announces that Lisa Estrada, senior vice president and chief compliance officer for Fresenius Medical Care North America (FMCNA), has joined the Leadership Committee for the New York City Kidney Walk to be held Sunday, Nov. 12, in Foley Square. As a member of the Leadership Committee, Estrada will help call att...

Quick Search
Advertisement
 

review and buy Diabetic Nephropathy - Kidney Disease market research data and corporate reports here